Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-Years Results from the GABI-R Registry
- Sprache
-
Englisch
- Identifier
-
1194236898
Beteiligte Personen und Organisationen
Gori, Tommaso
Achenbach, Stephan
Riemer, Thomas
Mehilli, Julinda
Nef, Holger M.
Naber, Christoph
Richardt, Gert
Wöhrle, Jochen
Zahn, Ralf
Neumann, Till
Kastner, Johannes
Schmermund, Axel
Hamm, Christian
Münzel, Thomas
Achenbach, Stephan
Riemer, Thomas
Mehilli, Julinda
Nef, Holger M.
Naber, Christoph
Richardt, Gert
Wöhrle, Jochen
Zahn, Ralf
Neumann, Till
Kastner, Johannes
Schmermund, Axel
Hamm, Christian
Münzel, Thomas
- URN
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
26.01.2023, 13:52 MEZ
Beteiligte
- Gori, Tommaso
- Achenbach, Stephan
- Riemer, Thomas
- Mehilli, Julinda
- Nef, Holger M.
- Naber, Christoph
- Richardt, Gert
- Wöhrle, Jochen
- Zahn, Ralf
- Neumann, Till
- Kastner, Johannes
- Schmermund, Axel
- Hamm, Christian
- Münzel, Thomas
Ähnliche Objekte (12)
Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Two‐year results from the German‐Austrian ABSORB registry
Coronary Stent Strut Fractures: Classification, Prevalence and Clinical Associations
Incidental Finding of Strut Malapposition Is a Predictor of Late and Very Late Thrombosis in Coronary Bioresorbable Scaffolds
Incidental finding of strut malapposition is a predictor of late and very late thrombosis in coronary bioresorbable scaffolds
Outcomes of 10,312 patients treated with everolimus‐eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium
Invasive treatment of NSTEMI patients in German chest pain units – evidence for a treatment paradox
Predictors for target vessel failure after recanalization of chronic total occlusions in patients undergoing surveillance coronary angiography
Ticagrelor or Prasugrel in patients with acute coronary syndromes and Diabetes Mellitus
The bioengineered combo dual-therapy CD34 antibody-covered sirolimus-eluting coronary stent in patients with chronic total occlusion evaluated by clinical outcome and optical coherence tomography imaging analysis
Assessment of impact of patient recruitment volume on risk profile, outcomes, and treatment effect in a randomized trial of ticagrelor versus prasugrel in acute coronary syndromes
Efficacy and safety of ticagrelor versus prasugrel in women and men with acute coronary syndrome: A pre-specified, sex-specific analysis of the ISAR-REACT 5 trial
Five‐year follow‐up of patients who underwent everolimus‐eluting bioresorbable scaffold implantation
Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Two‐year results from the German‐Austrian ABSORB registry
Coronary Stent Strut Fractures: Classification, Prevalence and Clinical Associations
Incidental Finding of Strut Malapposition Is a Predictor of Late and Very Late Thrombosis in Coronary Bioresorbable Scaffolds
Incidental finding of strut malapposition is a predictor of late and very late thrombosis in coronary bioresorbable scaffolds
Outcomes of 10,312 patients treated with everolimus‐eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium
Invasive treatment of NSTEMI patients in German chest pain units – evidence for a treatment paradox
Predictors for target vessel failure after recanalization of chronic total occlusions in patients undergoing surveillance coronary angiography
Ticagrelor or Prasugrel in patients with acute coronary syndromes and Diabetes Mellitus
The bioengineered combo dual-therapy CD34 antibody-covered sirolimus-eluting coronary stent in patients with chronic total occlusion evaluated by clinical outcome and optical coherence tomography imaging analysis
Assessment of impact of patient recruitment volume on risk profile, outcomes, and treatment effect in a randomized trial of ticagrelor versus prasugrel in acute coronary syndromes
Efficacy and safety of ticagrelor versus prasugrel in women and men with acute coronary syndrome: A pre-specified, sex-specific analysis of the ISAR-REACT 5 trial
Five‐year follow‐up of patients who underwent everolimus‐eluting bioresorbable scaffold implantation
Everolimus eluting bioresorbable vascular scaffolds in patients with acute coronary syndromes: Two‐year results from the German‐Austrian ABSORB registry
Coronary Stent Strut Fractures: Classification, Prevalence and Clinical Associations
Incidental Finding of Strut Malapposition Is a Predictor of Late and Very Late Thrombosis in Coronary Bioresorbable Scaffolds
Incidental finding of strut malapposition is a predictor of late and very late thrombosis in coronary bioresorbable scaffolds
Outcomes of 10,312 patients treated with everolimus‐eluting bioresorbable scaffolds during daily clinical practice – results from the European Absorb Consortium
Invasive treatment of NSTEMI patients in German chest pain units – evidence for a treatment paradox
Predictors for target vessel failure after recanalization of chronic total occlusions in patients undergoing surveillance coronary angiography
Ticagrelor or Prasugrel in patients with acute coronary syndromes and Diabetes Mellitus
The bioengineered combo dual-therapy CD34 antibody-covered sirolimus-eluting coronary stent in patients with chronic total occlusion evaluated by clinical outcome and optical coherence tomography imaging analysis
Assessment of impact of patient recruitment volume on risk profile, outcomes, and treatment effect in a randomized trial of ticagrelor versus prasugrel in acute coronary syndromes
Efficacy and safety of ticagrelor versus prasugrel in women and men with acute coronary syndrome: A pre-specified, sex-specific analysis of the ISAR-REACT 5 trial